February 6, 2018 / 12:32 PM / 2 months ago

BRIEF-Celgene Corp Announces Positive Results From The Pivotal Phase III ‘Optimismm’ Study Of Pomalyst/Imnovid

Reuters Staff

1 Min Read

Feb 6 (Reuters) - Celgene Corp:

* CELGENE CORPORATION ANNOUNCES POSITIVE RESULTS FROM THE PIVOTAL PHASE III ‘OPTIMISMM’ STUDY OF POMALYST/IMNOVID® FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA

* CELGENE CORP - STUDY MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.